EMA Revises Biosimilars Guideline - - BioPharm International

ADVERTISEMENT

EMA Revises Biosimilars Guideline


RELATED ARTICLES

More in GMPs/Validation

The European Medicines Agency (EMA) has revised their guideline on clinical and nonclinical issues related to biosimilars that contain biotechnology-derived proteins. The guideline includes requirements for marketing authorization of a biosimilar claiming to be similar to a biological product already marketed. The revised guideline updates the previous 2006 guidance and is open for public consultation for six months.

The revision provides additional guidance on the risk-based approach for the design of non-clinical studies; the use of pharmacodynamic markers for the demonstration of clinical comparability; study design (non-inferiority versus equivalence), choice of an appropriate patient population, and choice of surrogate endpoints in efficacy trials; the design of immunogenicity studies; and extrapolation of efficacy and safety from one therapeutic indication to another.

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Mylan to Acquire Abbott's Non-US Businesses in $5.3 Billion Stock Deal
July 14, 2014
Shire and AbbVie Discuss Possible Deal
July 14, 2014
Author Guidelines

Click here